In endemic areas, many people experience asymptomatic Plasmodium infections, particularly older children and adults, but their transmission contribution is unknown. Though not the exclusive determinant of infectiousness, transmission from humans to mosquitoes requires blood meals containing gametocytes. Gametocytes often occur at submicroscopic densities, challenging measurement in human populations. More sensitive molecular techniques allow better characterization of gametocyte epidemiologic patterns. Approximately 30 households were selected from each of eight sites in southern Malawi during two cross-sectional surveys. Blood was sampled from 623 people during the dry season and 896 the following rainy season. Among people PCR-positive for Plasmodium falciparum, mature gametocytes were detected by qRT-PCR. Regression models evaluated predictors of gametocyte carriage and density in the total population and among those with PCR-positive infections. The prevalence of gametocyte carriage by molecular testing was 3.5% during the dry season and 8.6% during the rainy season, and by microscopy 0.8 and 3.3%, respectively. Nearly half of PCR-positive infections carried gametocytes, regardless of recent symptom status. Among P. falciparum-infected people, only living in unfinished houses and age were significantly associated with gametocyte presence. Infected people in unfinished houses had higher odds of carrying gametocytes (OR 2.24, 95% CI 1.16–4.31), and 31% (95% CI 3–65%) higher gametocyte density than those in finished houses. School-age children (5–15 years), had higher odds than adults (≥16 years) of having gametocytes when infected (OR 2.77, 95% CI 1.47–5.19), but 31% (95% CI 11–47%) lower gametocyte density. Children <5 years did not have significantly higher odds of gametocyte carriage or density when infected than adults. School-age children frequently carry gametocytes in communities of southern Malawi and represent an under-recognized reservoir of infection. Malaria elimination strategies should address these frequently asymptomatic reservoirs, especially in highly endemic areas. Improved household construction may also reduce the infectious reservoir.
Background/Objectives: The COVID-19 pandemic presented an urgent global need to quickly vaccinate health workers (HWs). We used this unique circumstance to assess whether mature influenza vaccination programs for HWs facilitated rapid deployment of COVID-19 vaccines in low- and middle-income countries (LMICs). Methods: We used publicly available population-level COVID-19 vaccination coverage data from the World Health Organization (WHO) COVID-19 PowerBI Dashboard for 60 LMICs to investigate general population coverage with the COVID-19 vaccine over the first year of vaccine rollout. We also evaluated country-level policy and program data reported to the WHO–United Nations Children’s Fund (UNICEF) electronic Joint Reporting Form (eJRF) in 2022 or earlier to determine if the presence of a mature (≥2 years of influenza vaccine introduction in HWs prior to 2019) HW influenza vaccination program was associated with more rapid COVID-19 vaccine deployment and/or pandemic preparedness. We used a mixed-effects beta regression model to investigate whether having a mature HW influenza vaccination program was associated with COVID-19 vaccination coverage levels and/or deployment timeliness. Finally, to provide a better understanding of the possible relationship between the presence of a mature HW influenza vaccination program and the COVID-19 vaccine rollout, we analyzed interview data collected during COVID-19 vaccine post-introduction evaluations (cPIEs). Results: Twenty-four of our study countries (40%) had mature HW influenza vaccination programs prior to the COVID-19 pandemic, and 16 (27%) participated in cPIEs. The overall adjusted mean general-population COVID-19 vaccination coverage at 12 months post-deployment in countries with mature HW influenza vaccination programs was 46% (95% CI: (35%, 56%)), compared with 25% (95% CI: (19%, 32%)) in countries without such programs. Vaccination coverage was 2.5 times higher in countries with mature programs (adjusted odds ratio 2.5, 95% CI: (1.5, 4.5); p = 0.001). Conclusions: Our analysis suggests that mature influenza vaccination programs for HWs were associated with timelier and more complete COVID-19 vaccination rollout.
Background: Cameroon is the first country to introduce malaria vaccine (MV) into routine immunisation, following the pilot programme. The vaccine was introduced in 42 health districts across all 10 regions, with plans to scale up in additional districts in future. A mini-postintroduction evaluation (mini-PIE) was conducted to rapidly review the MV programme, make improvements and inform future strategies. Methods: A programme evaluation was conducted using desk review and field data collection with standardised interviews of immunisation staff and caregivers. A facilitated discussion was then conducted with key immunisation and malaria staff and partners using WHO intra-action review methodology. Results: The desk review found that completeness of monthly reports exceeded 95% in all regions in April 2024 except North-West and Adamawa (87%). Only 56% of eligible children received their first dose; however, coverage of the second and third doses was 31% and 28%, respectively. All 10 regions had high drop-out rates. Based on field data collection, 8 of 10 health facilities received communications materials for community awareness. Among caregivers interviewed, 88% (42/48) were aware of MV introduction (MVI); 60% (29/48) were informed by health workers and 81% (39/48) cited vaccine protection as the main reason to vaccinate children. 60% (29/48) knew the importance of continuing to use long-lasting insecticidal nets after malaria vaccination. During the facilitated discussion, 65% (n=37) of participants totally agreed that the mini-PIE methodology used was an effective way to identify challenges and lessons learnt. Conclusions: Cameroon’s MVI was largely successful, despite vaccine misinformation, demonstrating the importance of community dialogue and engagement in successful vaccine introduction. The mini-PIE methodology is recommended for other countries to adopt 4–6 months after introduction, including field work tailored to country needs and thorough desk review of key indicators conducted in advance to inform the facilitated discussion.
4 November 2026 in The American Journal of Tropical Medicine and Hygiene
: Malaria remains the primary cause of death among children younger than 5 years old in Africa. During 2019–2023, Ghana, Kenya, and Malawi piloted introduction of the first malaria vaccine, RTS,S/AS01, through the Malaria Vaccine Implementation Program. There are two malaria vaccines prequalified by the WHO: RTS,S/AS01 and R21/Matrix-M. The vaccines are recommended for children younger than 5 years old in endemic areas, prioritizing areas of moderate to high transmission. Data on vaccine introduction and doses shipped were obtained from the WHO and the United Nations Children’s Fund. As of December 2024, 17 countries in Africa had introduced the malaria vaccine with support from Gavi, the Vaccine Alliance, and another eight countries had approval for Gavi support. During 2023–2024, a total of 13,250,098 vaccine doses were shipped to countries. The introduction of the malaria vaccine presents an integration opportunity with preventive health services to reduce child morbidity and mortality.